# US 2023/0264171 A1 · Chromatography resin having an anionic exchange-hydrophobic mixed mode ligand

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0264171 A1
- Document ID: US20230264171A1
- Status: Published application
- Kind: A1
- Application number: 18/307,991
- Filed: 2023-04-27
- Published: 2023-08-24
- Earliest claimed: 2018-02-05
- Assignees: Bio-Rad Laboratories, Inc.
- Applicants: Bio-Rad Laboratories, Inc.
- Inventors: CHRISTOPHER BELISLE; HONG CHEN; YUEPING XU; JIALI LIAO; XUEMEI HE
- Web page: https://patentgrep.com/patent/US20230264171A1

## CPC

- B01J 20/262: {obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. obtained by polycondensation (macromolecular compounds obtained otherwise than by reactions only involving unsaturated carbon-to-carbon bonds per se C08G)}
- B01D 15/363: {Anion-exchange}
- B01D 15/3847: {Multimodal interactions}
- B01J 20/289: bonded via a spacer
- B01J 20/3208: {Polymeric carriers, supports or substrates}
- B01J 20/3219: {involving a particular spacer or linking group, e.g. for attaching an active group}
- B01J 20/3227: {by end-capping, i.e. with or after the introduction of functional or ligand groups}
- B01J 20/3248: {the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such}
- B01J 20/3253: {comprising a cyclic structure not containing any of the heteroatoms nitrogen, oxygen or sulfur, e.g. aromatic structures}
- B01J 20/3285: {Coating or impregnation layers comprising different type of functional groups or interactions, e.g. different ligands in various parts of the sorbent, mixed mode, dual zone, bimodal, multimodal, ionic or hydrophobic, cationic or anionic, hydrophilic or hydrophobic}
- B01J 20/3293: {Coatings on a core, the core being particle or fiber shaped, e.g. encapsulated particles, coated fibers}
- C07K 16/065: {Purification, fragmentation}
- C07K 16/22: against growth factors {; against growth regulators}
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- B01D 15/327: {with hydrophobic interaction}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- B01J: CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01D: SEPARATION (separating solids from solids by wet methods B03B, B03D; by pneumatic jigs or tables B03B; by other dry methods B07; magnetic or electrostatic separation of solid materials from solid materials or fluids, separation by high-voltage electric fields B03C; centrifuges, vortex apparatus B04; presses per se for squeezing-out liquid from liquid-containing material B30B9/02; treatment of water C02F, e.g. softening by ion-exchange C02F1/42; {arrangements of air intake cleaners in gas turbine plants F02C7/05} ; arrangements or mounting of filters in air-conditioning, air-humidification or ventilation F24F13/28)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Chromatography resins having mixed mode ligands and methods of using such resins are provided.

## Claims

### Claim 1

(canceled)

### Claim 2

A chromatography configuration comprising a packed column, fluidized column, expanded-bed column, monolith or porous membrane comprising a chromatography resin having the formula:
Chromatography matrix-(X1)-L-Ar-(X2)-Y
or a tautomer or an anionic salt thereof,
wherein:
X1 is a spacer;
X2 is C1 to C5 alkyl, C3 or C5 cycloalkyl;
L is NR8, O, or S wherein R8 is hydrogen or C1 to C6 alkyl;
Ar is a 6- to 10-membered aryl mono or bicylic ring optionally substituted with up to four C1 to C3 unsubstituted alkyl or C3 to C6 branched alkyl; and
Y is selected from the group consisting of:
wherein:
R1, R2, R3, R4, R5, R6, and R7 are each independently hydrogen or C1 to C6 alkyl;
if Y is
R2 is optionally joined to R3 to form a 4- to 7-membered heterocycle or R3 is optionally joined to R4 to form a 4- to 7-membered heterocycle;
if Y is
R1 is optionally joined to R2 to form a 4- to 7-membered heterocycle and R3 is optionally joined to R4 to form a 4- to 7-membered heterocycle; and
if Y is
R5 is optionally joined to R6 to form a 4- to 7-membered heterocycle or R6 is optionally joined to R7 to form a 4- to 7-membered heterocycle.

### Claim 3 (depends on 2)

The chromatography configuration of claim 2,
wherein:
X2 is C1-C3 alkyl;
L is NR8, O, or S wherein R8 is hydrogen or C1 to C3 alkyl;
Ar is phenyl or napthyl optionally substituted with up to four C1 to C3 unsubstituted alkyl; and
Y is selected from the group consisting of:
wherein:
R1, R2, R3, R4, R5, R6, and R7 are each independently hydrogen or C1 to C4 alkyl;
if Y is
R2 is optionally joined to R3 to form a 4- to 6-membered heterocycle or R3 is optionally joined to R4 to form a 4- to 6-membered heterocycle;
if Y is
R1 is optionally joined to R2 to form a 4- to 6-membered heterocycle and R3 is optionally joined to R4 to form a 4- to 6-membered heterocycle; and
if Y is
R5 is optionally joined to R6 to form a 4- to 6-membered heterocycle or R6 is optionally joined to R7 to form a 4- to 6-membered heterocycle.

### Claim 4 (depends on 2)

The chromatography configuration of claim 2, wherein:
X1 is a is selected from the group consisting of —O—CH2—, —O—CH2—CH2—, —O—CH2—CH2—CH2—, —O—CH2—CH2—CH2—CH2—, —O—CH2—CH(CH2—OH)—(O—CH2—CH(OH)—CH2)2—, —O—CH2—CH2—CH(CH2—OH)—(O—CH2—CH2—CH(OH)—CH2)2—, —O—CH2—CH(OH)—CH2—, —O—CH2—CH2—CH(OH)—CH2—CH2—, —O—CH2—CH(OH)—CH2—O—CH2—CH2—CH2—CH2—O—CH2—CH(OH)—CH2—, and —CO—NH—C(CH3)2—CO—;
X2 is —CH2—;
L is NR8 wherein R8 is hydrogen or —CH3;
Ar is phenyl optionally substituted with one or two C1 to C2 unsubstituted alkyl; and
Y is selected from the group consisting of:
wherein:
R1, R2, R3, R4, R5, R6, and R7 are each independently hydrogen or Ci to C3 alkyl.

### Claim 5 (depends on 2)

The chromatography configuration of claim 2, wherein R1-R7 are each independently hydrogen, C1 or C2 alkyl.

### Claim 6 (depends on 5)

The chromatography configuration of claim 5, wherein R1-R7 are each independently hydrogen or —CH3.

### Claim 7 (depends on 2)

The chromatography configuration of claim 2, wherein X1 is selected from the group consisting of —O—CH2—, —O—CH2—CH2—, —O—CH2—CH2—CH2—, —O—CH2—CH2—CH2—CH2—, and —O—CH2—CH(CH2—OH)—(O—CH2—CH(OH)—CH2)2—.

### Claim 8 (depends on 2)

The chromatography configuration of claim 2, wherein Ar is unsubstituted.

### Claim 9 (depends on 2)

The chromatography configuration of claim 2, wherein if Ar is phenyl, chromatography matrix-(X1)-L- is at a para or meta position relative to (X2)-Y.

### Claim 10 (depends on 2)

The chromatography configuration of claim 2, wherein chromatography matrix-X1-L-Ar-X2-Y is any one of the following structures:
Num-
Structure of Chromatography Resin (spheres
ber
represent matrix and spacer X1)
2
3
4
5
6
7a
7b
8a
8b
9
10
11
12
13
14
15
16
17
18
19
20
21
or
22

### Claim 11 (depends on 2)

The chromatography configuration of claim 2, wherein the anionic salt is hydrochloride or sulfate.

### Claim 12 (depends on 2)

A method of purifying a biomolecule, the method comprising:
contacting a sample comprising the biomolecule to a chromatography configuration of claim 2, thereby separating the biomolecule from a contaminant; and
collecting a purified biomolecule.

### Claim 13 (depends on 12)

The method of claim 12, wherein the purified biomolecule is a protein.

### Claim 14 (depends on 13)

The method of claim 13, wherein the protein is an antibody.

### Claim 15 (depends on 12)

The method of claim 12, wherein the sample comprises a monomeric antibody and antibody aggregates, the method comprises separating the monomeric antibody from the antibody aggregates, and the purified biomolecule comprises the monomeric antibody.

### Claim 16 (depends on 15)

The method of claim 15, wherein the contacting step comprises immobilizing the monomeric antibody to the chromatography matrix and the collecting step comprises eluting the monomeric antibody from the chromatography matrix.

### Claim 17 (depends on 16)

The method of claim 16, wherein the monomeric antibody is eluted with a pH gradient of a buffer in contact with the ligand from about 7-9 to about 3-6.

### Claim 18 (depends on 15)

The method of claim 15, wherein the contacting step comprises flowing the monomeric antibody through the chromatography matrix and the collecting step comprises collecting the monomeric antibody in the flow through.

### Claim 19

A chromatography configuration comprising a chromatography resin having the formula:
Chromatography matrix-(X1)-L-Ar-(X2)-Y
or a tautomer or an anionic salt thereof,
wherein:
X1 is a spacer;
X2 is C1 to C5 alkyl, C3 or C5 cycloalkyl or is absent;
L is NR8, O, or S wherein R8 is hydrogen or C1 to C6 alkyl;
Ar is a 6- to 10-membered aryl mono or bicylic ring optionally substituted with up to four C1 to C3 unsubstituted alkyl or C3 to C6 branched alkyl; and
Y is selected from the group consisting of:
wherein R1 and R4 are each independently hydrogen or C1 to C6 alkyl and R2 is joined to R3 to form a 4- or 5-membered heterocycle;
wherein R1 and R2 are each independently hydrogen or C1 to C6 alkyl and R3 is joined to R4 to form a 4- to 6-membered heterocycle; and
wherein R1, R2, R3, and R4 are each independently hydrogen or C1 to C6 alkyl and R5 is joined to R6 to form a 4- or 5-membered heterocycle or R1, R2, R3, R4, and R5 are each independently hydrogen or C1 to C6 alkyl R6 is joined to R7 to form a 4- or 5-membered heterocycle.

### Claim 20 (depends on 19)

The chromatography configuration of claim 19, wherein Y is
wherein R1 and R2 are each independently hydrogen or C1 to C6 alkyl and R3 is joined to R4 to form a 4- to 6-membered heterocycle.

### Claim 21 (depends on 19)

The chromatography configuration of claim 19, wherein Y is
wherein R1, R2, R3, R4, and R7 are each independently hydrogen or C1 to C6 alkyl and R5 is joined to R6 to form a 4- or 5-membered heterocycle or R1, R2, R3, R4, and R5 are each independently hydrogen or C1 to C6 alkyl and R6 is joined to R7 to form a 4- or 5-membered heterocycle.

### Claim 22 (depends on 19)

The chromatography configuration of claim 19, wherein Y is
wherein R1 and R4 are each independently hydrogen or C2 to C6 alkyl and R2 is joined to R3 to form a 4- or 5-membered heterocycle.

### Claim 23 (depends on 19)

A method of purifying a biomolecule, the method comprising:
contacting a sample comprising the biomolecule to a chromatography configuration of claim 19, thereby separating the biomolecule from a contaminant; and
collecting a purified biomolecule.

### Claim 24 (depends on 23)

The method of claim 23, wherein the purified biomolecule is a protein.

### Claim 25 (depends on 24)

The method of claim 24, wherein the protein is an antibody.

### Claim 26 (depends on 23)

The method of claim 23, wherein the sample comprises a monomeric antibody and antibody aggregates, the method comprises separating the monomeric antibody from the antibody aggregates, and the purified biomolecule comprises the monomeric antibody.

### Claim 27 (depends on 26)

The method of claim 26, wherein the contacting step comprises immobilizing the monomeric antibody to the chromatography matrix and the collecting step comprises eluting the monomeric antibody from the chromatography matrix.

### Claim 28 (depends on 27)

The method of claim 27, wherein the monomeric antibody is eluted with a pH gradient of a buffer in contact with the ligand from about 7-9 to about 3-6.

### Claim 29 (depends on 26)

The method of claim 26, wherein the contacting step comprises flowing the monomeric antibody through the chromatography matrix and the collecting step comprises collecting the monomeric antibody in the flow through.
